These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
60 related articles for article (PubMed ID: 21645282)
1. Serum levels of granulocyte colony-stimulating factor in JAK2 V617F-positive vs. negative erythrocytosis. Fujita H; Hamaki T; Ohwada A; Tomiyama J; Nishimura S Int J Lab Hematol; 2011 Dec; 33(6):e20-1. PubMed ID: 21645282 [No Abstract] [Full Text] [Related]
2. Isolated erythrocytosis in V617F negative patients with JAK2 exon 12 mutations: report of a new mutation. Bernardi M; Ruggeri M; Albiero E; Madeo D; Rodeghiero F Am J Hematol; 2009 Apr; 84(4):258-60. PubMed ID: 19229983 [No Abstract] [Full Text] [Related]
3. JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5. Cleyrat C; Jelinek J; Girodon F; Boissinot M; Ponge T; Harousseau JL; Issa JP; Hermouet S Leukemia; 2010 May; 24(5):1069-73. PubMed ID: 20182460 [No Abstract] [Full Text] [Related]
4. The incidence of the JAK2 V617F mutation in patients with idiopathic erythrocytosis. Percy MJ; Jones FG; Green AR; Reilly JT; McMullin MF Haematologica; 2006 Mar; 91(3):413-4. PubMed ID: 16503548 [TBL] [Abstract][Full Text] [Related]
5. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets. Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308 [TBL] [Abstract][Full Text] [Related]
6. Fast and reliable mutation detection of the complete exon 11-15 JAK2 coding region using non-isotopic RNase cleavage assay (NIRCA). Kambas K; Mitroulis I; Kourtzelis I; Chrysanthopoulou A; Speletas M; Ritis K Eur J Haematol; 2009 Sep; 83(3):215-9. PubMed ID: 19500139 [TBL] [Abstract][Full Text] [Related]
7. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype. Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178 [TBL] [Abstract][Full Text] [Related]
8. JAK2 mutation-negative secondary erythrocytosis in smoldering plasma cell myeloma: a case study and review of the literature. Lee SG; Lim G; Cho SY; Suh JT; Lee HJ; Baek SK; Lee WI; Yoon HJ; Park TS Acta Haematol; 2011; 126(3):169-71. PubMed ID: 21791913 [No Abstract] [Full Text] [Related]
9. Algorithmic evaluation of hereditary erythrocytosis: Pathways and caveats. Oliveira JL Int J Lab Hematol; 2019 May; 41 Suppl 1():89-94. PubMed ID: 31069987 [TBL] [Abstract][Full Text] [Related]
10. [Clinical study on relationship between protein tyrosine kinase JAK2 V617F mutation and high altitude polycythemia]. Ji LH; Li ZQ; Cui S Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):319-20. PubMed ID: 22781728 [No Abstract] [Full Text] [Related]
11. Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation. Er TK; Lin SF; Chang JG; Hsieh LL; Lin SK; Wang LH; Lin CW; Chang CS; Liu TC Clin Chim Acta; 2009 Oct; 408(1-2):39-44. PubMed ID: 19595684 [TBL] [Abstract][Full Text] [Related]
13. [Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders]. Zhang Y; Li L; Nie L; Yu Y; Yang YH; Zhang ZQ; Yang L; Xu SC; Xiao ZJ Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):105-9. PubMed ID: 18681311 [TBL] [Abstract][Full Text] [Related]
14. Isolated erythrocythemia: a distinct entity or a sub-type of polycythemia vera? Ohyashiki K; Kiguchi T; Ito Y; Gotoh A; Tauchi T; Miyazawa K; Kimura Y; Hisatomi H; Ohyashiki JH Jpn J Clin Oncol; 2008 Mar; 38(3):230-2. PubMed ID: 18292125 [No Abstract] [Full Text] [Related]
15. The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms. Trifa AP; Cucuianu A; Petrov L; Urian L; Militaru MS; Dima D; Pop IV; Popp RA Ann Hematol; 2010 Oct; 89(10):979-83. PubMed ID: 20422415 [TBL] [Abstract][Full Text] [Related]